Sign up to save your podcasts
Or
Share Inside the Issue: Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metastatic Breast Cancer
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Inside the Issue: Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metastatic Breast Cancer
Prof Peter Schmid from the Barts Cancer Institute in London, United Kingdom, and Dr Sara Tolaney from the Dana-Farber Cancer Institute in Boston, Massachusetts, review clinical trials investigating the role of antibody-drug conjugate-mediated therapies in the treatment of metastatic breast cancer.
View all episodes
By Dr. Neil Love
4.4
6262 ratings
Prof Peter Schmid from the Barts Cancer Institute in London, United Kingdom, and Dr Sara Tolaney from the Dana-Farber Cancer Institute in Boston, Massachusetts, review clinical trials investigating the role of antibody-drug conjugate-mediated therapies in the treatment of metastatic breast cancer.
More shows like Breast Cancer Update
View all
JAMA Editors' Summary
138 Listeners
NEJM This Week
323 Listeners
JAMA Clinical Reviews
498 Listeners
Lung Cancer Update
30 Listeners
Hematologic Oncology Update
76 Listeners
Prostate Cancer Update
14 Listeners
Gastrointestinal Cancer Update
17 Listeners
Gynecologic Oncology Update
12 Listeners
Dermatologic Oncology Update
0 Listeners
Research To Practice | Oncology Videos
121 Listeners
ASCO Daily News
57 Listeners
Mayo Clinic Talks
294 Listeners
The Curbsiders Internal Medicine Podcast
3,361 Listeners
The ONS Podcast
205 Listeners
The Clinical Problem Solvers
515 Listeners
Oncology Today with Dr Neil Love
59 Listeners
Two Onc Docs
193 Listeners
Oncology Nursing Update with Dr Neil Love: Focus on Oncology Nursing
0 Listeners